Fremanezumab-vfrm - Biologic Drug Details

Summary for fremanezumab-vfrm

Tradenames:	1
High Confidence Patents:	3
Applicants:	1
BLAs:	1
Suppliers: see list	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for fremanezumab-vfrm

Recent Litigation for fremanezumab-vfrm

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company	2018-09-27

See all fremanezumab-vfrm litigation

PTAB Litigation

Petitioner	Date
Eli Lilly and Company	2018-09-28

See all fremanezumab-vfrm litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for fremanezumab-vfrm Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for fremanezumab-vfrm Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2025-11-14	Company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2025-11-14	Company disclosures
Teva Branded Pharmaceutical Products R&d, Inc.	AJOVY	fremanezumab-vfrm	Injection	761089		2034-03-21	Company disclosures

3) Low Certainty: US Patents for fremanezumab-vfrm Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for fremanezumab-vfrm

Country	Patent Number	Estimated Expiration
Chile	2016002375
Costa Rica	9975
Slovenia	2380592

Supplementary Protection Certificates for fremanezumab-vfrm

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CA 2019 00036	Denmark		PRODUCT NAME: FREMANEZUMAB; REG. NO/DATE: EU/1/19/1358 20190401
39/2019	Austria		PRODUCT NAME: FREMANEZUMAB; REGISTRATION NO/DATE: EU/1/19/1358 20190401
1990038-0	Sweden		PRODUCT NAME: FREMANEZUMAB; REG. NO/DATE: EU/1/19/1358 20190401